Article PDF


chronic kidney disease, progression, quality of life, SF-36 questionnaire

Abstract views: 27
PDF Downloads: 12

How to Cite

Dudar , I., Loboda , O., Krasyuk І., & Alekseeva, V. (2020). INDICATORS OF QUALITY OF LIFE OF PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE II-IV. Medical Science of Ukraine (MSU), 16(3), 39-43.


Relevance. Chronic diseases have a long duration and a rather slow progression, and people who have such diseases want not only to live longer but also to live better. Therefore, quality of life (QOL) is one of the most important health issues for the treatment of chronic diseases.

Objective: to determine the features of QOL in patients with chronic kidney disease (CKD) stage II-IV.

Materials and methods. In 171 patients with CKD of II-IV centuries, in addition to general clinical and laboratory studies, QOL was studied using a questionnaire to assess the quality of life of SF-36. The questionnaire contains 36 questions of the main module, supplemented by multi-point scales aimed specifically at patients with CKD. The answers were evaluated in points - from 0 to 100. The higher the score, the better the patient's QOL. The total components were also calculated: physical total component, mental total component, total points. The obtained research data were subjected to statistical processing, which included parametric (t-test for samples with unrelated variants) and non-parametric (Mann-Whitney method) methods, correlation analysis was used.

Results. Most QOL indicators worsen significantly with the progression of CKD. The indicators of total QOL, as well as the indicator "the impact of the disease on everyday life" are most significantly reduced. Age correlates as much as possible with most indicators of QOL in patients with CKD. With age, the QOL of patients decreases, but the manifestations of the disease increase and the mental and physical condition of patients deteriorate. QOL parameters are probably directly and moderately correlated with hemoglobin levels. Most QOL parameters are significantly moderately correlated with systolic blood pressure and diastolic blood pressure. It is assumed that the correction of anemia and blood pressure control, in addition to a positive effect on disease progression and the occurrence and development of complications, will also improve QOL. There were no significant differences in the assessment of QOL in men and women.

Conclusions. QOL indicators decrease with the progression of CKD. Age, hemoglobin level, blood pressure affect QOL.
Article PDF


1. Atkins R.C., Zimmet P. Diabetic kidney disease: act now or pay later. Med J Aust. 2010; 25: 331-3. 2010 Mar 1;192(5):272-4. PMID: 20201761. URL:
2. Schieppati A., Remuzzi G. Chronic renal disease as a public health problem: epidemiology, social, and economic implications. Kidney Int. 2005; 2005 Sep; (98):S7-S10.
3. National Register of Patients with Chronic Kidney Disease: 2011 / Ed. Kolesnik M.O. Academy of Medical Sciences of Ukraine, Ministry of Health of Ukraine, Institute of Nephrology of the Academy of Medical Sciences of Ukraine. К., 2012. 89 p. [in Ukrainian].
4. Gilbertson D.T., Liu J., Xue J.L., Louis Th.A., Solid C.A., Ebben J.P., Collins A.J. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J. Am. Soc. Nephrol. 2005; 16: 3736-41. DOI:
5. Gonchar Y.I. [Quality of life and toxemia in patients treated with programmed hemodialysis] [author's ref. Dissertation] 14.01.37. Institute Of Nephrology. Kyiv, 2008. 24 p. [in Ukrainian].
6. Gayle F., Soyibo A.K., Gilbert D.T. [et al.] Quality of life in end stage renal disease: a multicentre comparative study. West Indian. Med. J. 2009; 58(3): 235-42.
7. Ospanova TS, Semidotskaya Zh. D., Kotulevich N. Ya., inventor; Kharkiv State Medical University (UA), assignee. [A method of assessing the quality of life of patients treated with program dialysis]. Ukraine patent № u 2003119917, 04.11.2003. bulletin № 6/2004, 15.06.2004. [in Ukrainian].
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.